Clinical trials: Carcinoma, Bronchogenic
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Lung Cancer, Metastatic Cancer
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01302808
- Testing
- Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon…
- Trial name
- NCT00064350
- Testing
- Sorafenib
- Where
- 141 sites in United States
- Volunteers
- 342 people
- Sponsor
- Eastern Cooperative Oncology Group
Hematopoietic and Lymphoid Cell Neoplasm, Lung Non-Small Cell Carcinoma
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
This trial evaluates the risk of chemotherapy toxicity in older patients with blood cancer or non-small cell lung cancer. The purpose of this study is to describe a patient's wellness before and after chemotherapy treatment.
- Trial name
- NCT05106374
- Testing
- Biospecimen Collection, Cognitive Assessment, Physical Performance Testing
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Neoplasms, Lung Neoplasms
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
TROPION-DM/BrUOG-431 is a prospective, , phase 2 trial with two non-comparative cohorts analyzed jointly for primary endpoint in adult patients with either (Cohort 1:) advanced/metastatic hormone-receptor positive ([HR+]…
- Trial name
- NCT06974604
- Testing
- Dexamethasone oral
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brown University
Non-Small Cell Lung Cancer
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung…
- Trial name
- DELINOR (NCT05834348)
- Testing
- lorlatinib, crizotinib, brigatinib
- Where
- Norway
- Volunteers
- 5,279 people
- Sponsor
- Pfizer
Small Cell Lung Cancer
A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy.
- Trial name
- RASTEN (NCT00717938)
- Testing
- cisplatinum or carboplatin and e.g.etoposide., cisplatinum or carboplatin and e.g.etoposide+enoxaparin
- Where
- 16 sites in Sweden
- Volunteers
- 390 people
- Sponsor
- Lund University Hospital
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00278148
- Testing
- carboplatin, Erlotinib, paclitaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nathan Pennell, MD, PhD
Non-Small Cell Lung Cancer
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.
- Trial name
- NCT01103089
- Where
- 11 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Non-Small Cell Lung Cancer
The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients
This study is designed to evaluate the predicted potential of quantitative T cell repertoire (TCR) of T cell receptor chains using next-generation sequencing (NGS) in the treatment of the anti-programmed death-ligand 1 (PD-L1)…
- Trial name
- NCT03228368
- Testing
- Atezolizumab (MPDL3280A)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
NSCLC (Non-small Cell Lung Carcinoma)
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is…
- Trial name
- NCT02119650
- Testing
- Ruxolitinib, Pemetrexed, Cisplatin
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- Incyte Corporation
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Melanoma Stage III, Melanoma Stage IV
Appropriate Dosing to Optimise Personalised Cancer Treatments
This is a pilot study to assess feasibility of dried blood spot (DBS) samples for pharmacokinetic measurements of targeted anti-cancer drugs in oncology patients such as patients with BRAF-mutant melanoma receiving targeted…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Ovarian Cancer, Renal Cancer Stage III
- Trial name
- ADOPT (NCT04154163)
- Testing
- Dried blood Spot (DBS), Venous blood sampling
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Dundee
Carcinoma, Non-Small-Cell Lung, Bevacizumab
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
This is a prospective, single-arm, single-center, phase II trial designed to evaluate the efficacy and safety of bevacizumab combined with a double dose of icotinib as a first-line treatment for patients with advanced…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Bevacizumab, Tyrosine Kinase Inhibitor, EGFR L858R
- Trial name
- NCT05263947
- Testing
- Bevacizumab, Icotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer Non-Small Cell Cancer (NSCLC)
Real-World Immuno-Radiotherapy for Advanced NSCLC
The optimal combination strategy for radiotherapy combined with immunotherapy (iRT) in advanced non-small-cell lung cancer (NSCLC) remains unclear, and there is a lack of real-world data to validate its efficacy.
- Trial name
- OCEANUS (NCT06747026)
- Testing
- initial Sequential iRT, initial Concurrent iRT, RT with maintenance of ICI
- Where
- Hong Kong
- Volunteers
- 338 people
- Sponsor
- Fengming Kong
Small Cell Lung Carcinoma
Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer
As the gene polymorphism of uridine diphosphate glucuronosyl transferase 1A1(UGT1A1)is related to the side effect of diarrhea induced by irinotecan.
- Trial name
- TDICC (NCT01977235)
- Testing
- Irinotecan, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 110 people
- Sponsor
- Third Military Medical University
Carcinoma, Non-Small-Cell Lung, Neoplasms
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
The study is primarily designed to assess the safety and tolerability of escalating oral doses of Debio 1143 and preliminary anti-tumour activity when combined with the standard dose of avelumab in participants with advanced…
- Trial name
- NCT03270176
- Testing
- Debio 1143, Avelumab
- Where
- 9 sites in Canada, Poland and 1 more
- Volunteers
- 54 people
- Sponsor
- Debiopharm International SA
Lung Cancer
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have relapsed or…
- Trial name
- NCT00022711
- Testing
- temozolomide
- Where
- 17 sites in United States
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
This study is a randomized phase III trial that aiming to investigate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) guided hypofractionated radiotherapy (hypo-RT) in patients with locally advanced…
- Trial name
- NCT06545747
- Testing
- DCE-MRI based split-course hypo-RT, CT based split-course hypo-RT, Concurrent chemotherapy
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.